Autolus Therapeutics plc (AUTL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Christian Martin Itin Ph.D. | CEO & Director | 2.57M | -- | 1964 |
| Mr. Alex Driggs | Senior VP of Legal Affairs & General Counsel and Secretary | -- | -- | 1976 |
| Dr. Christopher Williams | Chief Business Officer | -- | -- | 1980 |
| Dr. Matthias Will M.D. | Senior VP & Chief Development Officer | -- | -- | 1973 |
| Dr. Martin Pule M.D., MBBS | Founder, Senior VP & Chief Scientific Officer | -- | -- | 1972 |
| Mr. Robert F. Dolski | Senior VP, CFO & Principal Accounting Officer | -- | -- | 1971 |
| Mr. Christopher Vann | Senior VP & COO | -- | -- | 1965 |
| Mr. David Brochu | Senior VP & Chief Technical Officer | -- | -- | 1956 |
| Ms. Olivia Manser | Director of Investor Relations | -- | -- | -- |
| Mr. Alexander Swan | Senior VP & Chief Human Resources Officer | -- | -- | 1965 |
Autolus Therapeutics plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 647
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Corporate Governance
Upcoming Events
May 8, 2025 at 11:00 AM UTC
Autolus Therapeutics plc Earnings Date
Recent Events
September 30, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission